We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Open Orphan Plc | LSE:ORPH | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.00 | 9.50 | 10.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/11/2020 09:11 | I also would have thought that the staff would be givern shares in the company as an added incentive. When I worked for Chase they did that | malcolmmm | |
19/11/2020 09:11 | o/t P, not more in common. Where did you work in Switzerland? What sgs does depends on what they want, if anything. If they want chimagents back, they could easily offer them a higher rate, and even pay any penalties to hvivo if they break a contract. If sgs want the challenge study business (which to my mind is the only feasible requirement - you can't build a business just relying on a couple of people, as they've found out) then i'd guess they'd takeout the whole of orph. the other bits could also fit in with their conglomerate status. Although pure speculation, i'd estimate there's a real chance of sgs wanting orph - it makes a lot of business sense to sgs imv. (I'm not saying 'sgs is about to takeover orph'). | pierre oreilly | |
19/11/2020 09:11 | Orph has now got to be worth nearer the £1 mark Surely Although in the real world whole PLC company sales are a rare beast. Partial PLC company sales less so | judijudi | |
19/11/2020 09:09 | Pogue So would you be happy as a newly poached (from SGS) staff member to think that your CEO is talking about possibly selling to the company you have just left to join Orph? I think it must be unsettling for most of the staff to be told by their CEO that the company is up for sale bwtfdik | judijudi | |
19/11/2020 09:09 | I am thinking that once ORPH get the go ahead from the ethics committee that they will be bid for by a big phama or two. | malcolmmm | |
19/11/2020 09:07 | pogu, I would agree with that. Whilst money is an important factor for us all, and I am sure it will have been worth their while, people leave for other reasons and going back does not always turn out well. I am sure CF will have worked his charms on them l and I can imagine that whilst expecting a lot, he will be a decent and straight forward guy to work for and with. | m5 | |
19/11/2020 08:58 | Warranty I am guessing here but I suggest CF brought back the old team on two points, one they were going to be paid as contractors rather than staff, the setting up of the little company they are all in suggests that, hence they got a large pay boost. Secondly I suspect the carrot of working at the lead company in a booming sector appeals to their egos as they will be on committees etc and regarded as the world leaders in their field this is important to scientific types in my experience. Edit also from experience Switzerland is rock hard expensive to live in it makes London look cheap. | pogue | |
19/11/2020 08:53 | hxxps://asm.org/Arti | troutisout | |
19/11/2020 08:50 | Is there anything to stop SGS from poaching the people and others back from Orph/Hvivo? They must have deeper pockets than Orph and it would be cheaper than buying the company with bits they don’t really want. Do we have the main people tied to contracts that can’t be broken? | warranty | |
19/11/2020 08:48 | To me the RNS read as we are setting the standard others must follow and our procedures for manufacturing will be used as the starting point for the standards I expect, you need a base template to start with to work on. I have written standards in engineering so am familiar with the process. Clearly ours will then be the basis of the standard since we are in charge of setting it up and will have most influence on the committee. The mere fact that a standard for manufacturing agents outside of the labs they are currently made in points to a dramatic expansion in the industry outside its current small base again verifying CFs optimism on a decade of virus challenge studies. In the last presentation CF was a bit more cagey on when he plans to sell ORPH that can be read two ways one, he is looking at a longer time frame, two, he is well on the way to doing it and is keeping stum. Who knows which but worth probing him tonight on how he is feeling if a bidder appeared since we seem to be at the beginning of a sectorial boom which we ride or sell into based on large future profits. | pogue | |
19/11/2020 08:42 | I think the welcome news is worth more than 1/2p | readdin | |
19/11/2020 08:35 | Cheers guys, thanks for posting it up. | m5 | |
19/11/2020 08:29 | m5, cheers, I've found it now on company website. | owenski | |
19/11/2020 08:29 | Since the biondvax uni flu vaccine failed phase 3, afaiia, there are currently no phase 3 uni flu trials on going. So imutex is the most advanced having passed stage 2 and in addition 3 challenge studies, as c pointed out.. No idea whether there are other candidates which have passed phase 2. Whatever, that's why imutex has a high value, some big pharma interested in a uni flu vaccine could take the risk and fund phase 3, something orph won't do. What's likely imv (warning, speculation) is that c will try to reverse Imutex into the boindvax remnants and therefore acquire a nas quote and raise cash on the nas during the reversal. If that happens - and it's exactly where C's expertise lies - then we'll all get a Divi in the form of new biondvax shares. ........... The Rns is great for stating to the world that hvivo is the accepted and respected world leader in challenge trials. | pierre oreilly | |
19/11/2020 08:28 | if anyone want to register for tonight's presentation on Pro-active - | owenski | |
19/11/2020 08:25 | https://www.openorph | gregb | |
19/11/2020 08:24 | molatov So it’s one of the first 2 or a mixture of both Hopefully just a very pro active ceo trying to get the “Orph” word out there | judijudi | |
19/11/2020 08:24 | owenski19 Nov '20 - 08:20 - 8400 of 8402 It's on her somewhere. I have not go it to hand. | m5 | |
19/11/2020 08:21 | Was already planned on the website. | molatovkid | |
19/11/2020 08:20 | I wonder why he is doing another interview so soon after the last one Does he like the limelight? Is he being a very pro active ceo? Or has he something new to discuss? | judijudi | |
19/11/2020 08:20 | m5, what's the link for the presentation tonight? | owenski | |
19/11/2020 08:15 | Good to see the Company spell out, in simple English, what a CHIM is in the RNSNON.... | troutisout | |
19/11/2020 08:15 | You have to say that we must be in SGS's sights. Its more difficult to rationalize that we will not be. CF will certainly get the best deal he can, but do wish we were at a higher level share price wise. Looking forward to hearing CF tonight. He will have had a little stick this week so I am looking forward to hearing his tone and how he attacks that tonight. | m5 | |
19/11/2020 08:04 | disco, Predictive text I will however be more careful. Just for you 😀 | judijudi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions